MicroRNA dynamics, PTEN/PI3K/AKT signaling, and their relationship to breast cancer: prospects for pharmaceuticals and natural product application
Breast Cancer, PI3K/PTEN/AKT signaling pathway, microRNAs, Natural Products, Potential drugs.
Breast Cancer Research and Treatment
This is an international arena for the discussion and resolution of ongoing controversies in breast cancer treatment, or for the consideration of thoughtful speculation and comments on current work.
Body composition and chemo toxicities
Current dosing is based on body weight and predicted Body Surface Area (BSA). These parameters do not take into consideration the individual variations of fat mass (FM) and fat-free mass (FFM) that affect pharmacokinetics.
CDK4/6 inhibitors vs. weekly paclitaxel for ER+/HER2- advanced breast cancer with impending or established visceral crisis
In this retrospective study, patients with ER+/HER2- advanced breast cancer and impending or established visceral crisis had better outcomes when treated with a CDK4/6 inhibitor + endocrine therapy compared to weekly paclitaxel.
